Researchers have found that a new mechanism in which an antibody can prevent allergic reactions and breakthrough could pave the way for even more effective allergy medicine.
According to the new research, a new mechanism in antibody can prevent allergic reactions, in a wide range of people.
Scientists have found that breakthrough could pave the way for a highly effective allergy medicine.
The new mechanism in which an antibody interacts in a process which is complex biochemical in the human body, the process prevents the human allergy antibody (IgE) from getting attach to cells. Thus, it keeps preventing all allergic symptoms in the human body from occurring.
Edzard Spillner of the Aarhus University in Denmark, said, “We can now describe the interaction of this antibody with its target and the conformational changes very accurately.”
Spillner went on to say, “This allows us to understand, how it interferes with the IgE and its specific receptors on the immune cells of the body, which are responsible for releasing histamine in an allergic reaction.”
A person with allergy produces IgE molecules in high level against external allergens while exposed to them. These high levels of IgE molecules are loaded onto the effector cells of the immune system and circulate in the blood which prompts the production of histamine which turns into a quick allergic reaction in the body.
The main function performed by the antibody is that it interferes with binding of IgE molecules to the two specific effectors — CD23 and FceRI. It makes impossible for the allergy molecule to bind on the immune cells.
The study published in the journal Nature Communications, suggests that even after binding the IgE molecules to its receptors, that the antibody also removes the IgE.
Spillner said, “Once the IgE on immune cells can be eliminated, it doesn’t matter that the body produces millions of allergen-specific IgE molecules. When we can remove the trigger, the allergic reaction and symptoms will not occur.”
The researchers found the antibody effective, at the very same time it is considerably smaller than therapeutic antibodies which are presently used to produce allergy medicine.
Spillner said, “It is a so called single domain antibody which easily produced in processes using only microorganisms. It is also extremely stable, and this provides new opportunities for how the antibody can be administered to patients.”
The new antibody unlike most therapeutic antibodies already available in the market, does not necessarily have to be injected into the human body as the chemical structure makes it suitable to be might be inhaled or swallowed. These new methods of consumption will make it more comfortable, easy, and cheap for the patients to handle.